Anthera Pharmaceuticals, Inc.
ANTH · OTC
3/31/2018 | 12/31/2017 | 9/30/2017 | 6/30/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | -$0 | $0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| EPS | -0.2 | -0.76 | -0.43 | 0.92 |
| % Growth | 73.7% | -76.7% | -146.7% | – |
| EPS Diluted | -0.2 | -0.76 | -0.43 | 0.92 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | -$0 | -$0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |